Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) shares advanced 3.83% in last trading session and ended the day at $5.69. SPPI Gross Margin is 82.00% and its has a return on assets of -10.70%. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) quarterly performance is -24.03%.
On 20 November, Spectrum Pharmaceuticals (NASDAQ: SPPI), announced the Company has submitted an IND application to the U.S. Food and Drug Administration (FDA) and plans to initiate a Phase 2 breast cancer study in the U.S. as soon as possible.
Spartan Motors Inc. (NASDAQ:SPAR) ended the last trading day at $3.67. Company weekly volatility is calculated as 2.49% and price to cash ratio as 6.02. Spartan Motors Inc. (NASDAQ:SPAR) showed a weekly performance of 1.38%.
Spartan Motors, Inc. (NASDAQ:SPAR) announced that its Board of Directors has declared a cash dividend of $0.05 per share of common stock. The Charlotte, Michigan-based manufacturer of custom chassis, emergency response and delivery and service vehicles reported its semi-annual dividend will be payable on December 17, 2015 to shareholders of record at the close of business on November 12, 2015.
On 25 November, Stemline Therapeutics, Inc. (NASDAQ:STML) shares moved up 0.12% and was closed at $8.37. STML EPS growth in last 5 year was -16.90%. Stemline Therapeutics, Inc. (NASDAQ:STML) year to date (YTD) performance is -50.94%.
Boot Barn Holdings, Inc. (NYSE:BOOT) shares moved up 6.87% in last trading session and ended the day at $11.36. BOOT Gross Margin is 31.90% and its has a return on assets of 2.70%. Boot Barn Holdings, Inc. (NYSE:BOOT) quarterly performance is -45.78%.
Boot Barn Holdings (NYSE:BOOT) was downgraded by stock analysts at Wells Fargo from an “outperform” rating to a “market perform” rating in a report released on Thursday, Market Beat Ratings reports.
PTC Therapeutics, Inc. (NASDAQ:PTCT) caters to the Healthcare space. Its weekly performance is -14.88%. On the last day of trading company shares ended up at $29.52. PTC Therapeutics, Inc. (NASDAQ:PTCT) distance from 50-day simple moving average (SMA50) is -11.43%.
On 19 November, PTC Therapeutics, Inc. (NASDAQ:PTCT) announced that it has completed enrollment of ACT CF, the company’s second Phase 3 clinical trial of Translarna™ (ataluren) for patients with nonsense mutation cystic fibrosis (nmCF). Nonsense mutations in cystic fibrosis are categorized as Class I mutations, which are the most difficult to treat, as they result in little or no production of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Approximately 10 percent of cystic fibrosis patients have their disease as a result of a nonsense mutation.
Leave a Reply